Özcan Pirilti, Düzgün Özgül
Department of General Surgery, Cerrahpaşa Faculty of Medicine, Istanbul University, 34116 Istanbul, Turkey.
Department of Surgical Oncology, İstanbul Umraniye Training and Research Hospital, University of Health Sciences, 34764 Istanbul, Turkey.
J Pers Med. 2024 Jul 11;14(7):742. doi: 10.3390/jpm14070742.
Ovarian cancer maintains the highest mortality rate among gynecological malignancies. Unfortunately, two-thirds of cases are diagnosed at an advanced stage with the presence of peritoneal carcinomatosis. In this study, we aimed to present the 7-year results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in cases where peritoneal carcinomatosis developed during the medical oncological treatment and follow-up after primary high-grade serous ovarian cancer debulking surgeries.
Data from 63 patients collected prospectively in our clinic were retrospectively evaluated.
Postoperative Clavien-Dindo grade 3-4 complications occurred in 12 cases (19%) and 14 cases (22.2%), respectively. CD grade 3a complications developed in four cases (6.3%), which were treated with percutaneous drainage catheters, while CD grade 3b complications occurred in eight cases (12.7%), and these cases underwent reoperation. Five cases (7.9%) experienced mortality within the first 30 days. The mean survival time was determined as 44.99 months (36.33-53.65), while the median survival time was 56 months.
In selected patients requiring redo surgery due to recurrent ovarian cancer, secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with longer overall survival and should be considered in the treatment of advanced-stage disease. Further large-scale randomized controlled trials are needed in this regard.
卵巢癌在妇科恶性肿瘤中死亡率最高。不幸的是，三分之二的病例在晚期被诊断出来，伴有腹膜癌转移。在本研究中，我们旨在呈现细胞减灭术和热灌注化疗治疗原发性高级别浆液性卵巢癌肿瘤细胞减灭术后医学肿瘤治疗及随访期间发生腹膜癌转移病例的7年结果。
回顾性评估了前瞻性收集的我院63例患者的数据。
术后Clavien-Dindo 3-4级并发症分别发生在12例（19%）和14例（22.2%）患者中。4例（6.3%）出现CD 3a级并发症，通过经皮引流导管治疗，8例（12.7%）出现CD 3b级并发症，这些病例接受了再次手术。5例（7.9%）在术后30天内死亡。平均生存时间为44.99个月（36.33 - 53.65），中位生存时间为56个月。
对于因复发性卵巢癌需要再次手术的特定患者，二次细胞减灭术和热灌注化疗与更长的总生存期相关，在晚期疾病的治疗中应予以考虑。在这方面需要进一步开展大规模随机对照试验。
